SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph read 2 numbers from its abstract, feeding 1 cell of the map, but none could be read as for or against, so it casts no vote. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
Tirzepatide was not associated with a statistically significant increase in arrhythmic outcomes, including atrial fibrillation (AF) (RR 1.39, 95% CI 0.53 to 3.67) and atrial flutter (AFL) (RR 1.14, 95% CI 0.20 to 6.55).
Tirzepatide was not associated with a statistically significant increase in arrhythmic outcomes, including atrial fibrillation (AF) (RR 1.39, 95% CI 0.53 to 3.67) and atrial flutter (AFL) (RR 1.14, 95% CI 0.20 to 6.55).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
GIP/GLP-1 & amylin agonists×cardiovascular events
No readable resultOpen on the map →What to test next →2 readable studies in this cell: 2 favour the treatment, 0 find no difference, 0 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
backgroundTirzepatide, a dual GIP/GLP-1 receptor agonist, is effective for glycemic control in type 2 diabetes (T2D), but its impact on cardiovascular (CV) and neurological safety remains uncertain. This meta-analysis evaluated the risks of arrhythmic, major CV, and neurological outcomes associated with tirzepatide.
methodsA comprehensive search of the PubMed, Embase, and Cochrane databases was conducted to identify eligible randomized controlled trials (RCTs) reporting arrhythmic, major CV, and neurological outcomes published up to February 2025. Additionally, subgroup analyses were conducted by age, BMI, diabetes duration, and comparator type.
resultsTwelve RCTs involving 10,615 patients with T2D were included. Tirzepatide was not associated with a statistically significant increase in arrhythmic outcomes, including atrial fibrillation (AF) (RR 1.39, 95% CI 0.53 to 3.67) and atrial flutter (AFL) (RR 1.14, 95% CI 0.20 to 6.55). For major CV outcomes, no significant differences were observed for acute myocardial infarction (RR 0.66, 95% CI 0.38 to 1.17) or coronary artery disease (RR 0.62, 95% CI 0.32 to 1.18). Neurologically, tirzepatide significantly increased the risk of dizziness (RR 1.64, 95% CI 1.04 to 2.57), whereas the risks of headache (RR 1.00, 95% CI 0.65 to 1.55) and transient ischemic attack (RR 1.43, 95% CI 0.44 to 4.61) were not significant. Subgroup analyses suggested higher dizziness risk in patients aged ≤ 60 years.
conclusionsTirzepatide does not significantly increase arrhythmic or major CV risks but is associated with a higher risk of dizziness. Findings from CV and neurological perspectives support targeted patient monitoring and guide future prospective studies.
Indexed as
Identifiers
41402646What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.